BiotechTube
Breathe BioMedical

Breathe BioMedical

Moncton, United States· Est.
breathebiomedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.7M

Overview

Breathe BioMedical is a private, pre-revenue diagnostics company pioneering a breath-based analytics platform for early cancer detection. Its lead program targets breast cancer, specifically as an adjunctive screening tool for women with dense breast tissue, where mammography sensitivity is low. Recent research demonstrated 88.2% accuracy in distinguishing early-stage breast cancer from controls, with density not affecting accuracy. The company is led by an experienced medtech team and is currently conducting a multi-center clinical trial to validate its technology.

Oncology

Technology Platform

Breath analytics platform comprising a proprietary Breath Sampler for standardized collection and spectrometry for analysis of volatile organic compounds (VOCs) to create disease-specific breath signatures.

Funding History

2
Total raised:$6.7M
Series A$5.2M
Seed$1.5M

Opportunities

A large addressable market exists in adjunctive breast cancer screening for the 40-50% of women with dense breast tissue, where current mammography is less effective.
A successful, non-invasive breath test could integrate seamlessly into screening workflows, improving early detection rates and optimizing healthcare resource utilization.
Platform potential allows for future expansion into lung cancer and other disease areas.

Risk Factors

Key risks include the need to validate initial promising accuracy (88.2%) in larger, multi-center clinical trials under real-world conditions.
The company must also navigate the complex FDA regulatory pathway for a novel diagnostic and subsequently secure insurance reimbursement, which is critical for commercial adoption.

Competitive Landscape

The non-invasive cancer detection space is competitive, including other liquid biopsy (blood-based) tests and imaging advancements. While breath-based diagnostics is a nascent field, several companies are exploring similar VOC analysis for various diseases. Breathe BioMedical's focused strategy on a specific high-need population (women with dense breasts) provides a clear differentiation and initial market entry point.

More companies in United States →